Teladoc, Inc. (TDOC) Receives $38.18 Average Target Price from Analysts
Shares of Teladoc, Inc. (NYSE:TDOC) have been given a consensus recommendation of “Buy” by the fifteen ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $39.09.
TDOC has been the subject of several recent analyst reports. Cowen Inc restated an “outperform” rating and set a $39.00 price objective (up previously from $36.00) on shares of Teladoc in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. boosted their price objective on shares of Teladoc from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday. Canaccord Genuity set a $42.00 price objective on shares of Teladoc and gave the stock a “buy” rating in a research report on Friday, November 17th. SunTrust Banks, Inc. restated a “buy” rating and set a $40.00 price objective on shares of Teladoc in a research report on Friday, November 3rd. Finally, BidaskClub downgraded shares of Teladoc from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd.
In related news, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the completion of the sale, the chief executive officer now owns 838,261 shares in the company, valued at approximately $26,908,178.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $34.04, for a total transaction of $340,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 135,000 shares of company stock valued at $4,408,700. 4.47% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC purchased a new stake in Teladoc in the 2nd quarter valued at $104,000. Bank of Montreal Can raised its position in Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after purchasing an additional 2,397 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Teladoc in the 2nd quarter valued at $135,000. Fred Alger Management Inc. purchased a new stake in Teladoc in the 2nd quarter valued at $139,000. Finally, Ameritas Investment Partners Inc. raised its position in Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after purchasing an additional 2,707 shares during the last quarter.
Shares of Teladoc (NYSE TDOC) traded up $1.25 during trading hours on Monday, hitting $35.25. 833,891 shares of the stock traded hands, compared to its average volume of 1,089,488. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc has a twelve month low of $15.65 and a twelve month high of $37.55.
Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.25). The company had revenue of $68.70 million for the quarter, compared to analysts’ expectations of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The firm’s quarterly revenue was up 112.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.33) EPS. equities research analysts forecast that Teladoc will post -1.57 EPS for the current year.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.